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Abstract  
 
Aim. We aimed at exploring the activation pattern of mTOR pathway in sporadic and 
hereditary pheochromocytomas (PCC) and paragangliomas (PGL).  
Methods. A total of 178 PCC and 44 PGL, already characterized for the presence of germline 
mutations in VHL, RET, NF-1, MAX, SDHA, SDHB, SDHC, SDHD and somatic mutations in 
VHL, RET, H-RAS and MAX, were included into five TMAs and tested using 
immunohistochemistry for mTOR and Rictor and the phosphorylated forms of mTOR, 
p70S6K, AMPK, AKT, 4E-BP1, S6 and Raptor.  
Results. The positive correlation among most of the molecules investigated proved the 
functional activation of the mTOR pathway in PCC/PGL. Total mTOR, p-S6K and p-S6 and 
mTORC1-associated molecules p-Raptor and p-AMPK were all significantly over-expressed 
in PGLs rather than in PCCs, and in head and neck rather than in abdominal locations. None 
of the markers, except the low expression of p-mTOR, was associated to malignancy. Cluster 
1 had higher total mTOR, p-Raptor and p-S6 expression than Cluster 2 PCC/PGL. In contrast, 
p-mTOR and mTORC2-associated molecule Rictor were significantly over-expressed in 
Cluster 2 tumors. Within Cluster 1, molecules active in the mTORC1 complex were 
significantly over-expressed in SDHX- as compared to VHL-mutated tumors.  
Conclusions. In summary, the mTOR pathway is activated in a high proportion of PCC/PGLs, 
with a preferential over-activation of mTORC1 complex in PGLs of the head and neck and/or 
harbouring SDHX mutations. 
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Introduction 
 
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors arising 
from chromaffin cells of the adrenal medulla or of paraganglia in the head and neck region or 
along the sympathetic trunk. PCC and PGL can be either familial or sporadic. Germline 
mutations in the SDHA, SDHB, SDHC, SDHD, SDHAF2 (together SDHX), VHL, RET, NF1, 
TMEM127, MAX, KIF1B, PHD2, FH or the most recently identified HIF2A are identified in 
about 40% of PCC/PGL patients [1]. Somatic mutations in RET, VHL, MAX and HIF2A genes 
are also reported in 17% of sporadic tumors. Moreover, recent reports identified somatic NF1 
and H-RAS mutations in 22-26% and 5-7% of sporadic PCCs/PGLs, respectively [2-5]. 
Although the disease is the perfect example of genetic heterogeneity, two main transcriptomic 
signatures have been evidences. The first one, named cluster 1, is enriched with VHL- , 
SDHX- and FH-mutated tumors, and shares a pseudohypoxic profile. The second one, named 
cluster 2, groups tumours related to mutations in RET, NF1, TMEM127 and MAX, and 
involves a kinase pathway [1]. The first integrative genomic study, recently published, 
demonstrated the crucial role of predisposing mutations as being the main drivers of 
PCC/PGLs [6]. 
The mTOR pathway is of great interest since it functionally interacts with genes whose 
alterations characterize both PCC/PGL clusters. In fact, several cancer models demonstrated 
that the components of the mTOR pathway have signalling interactions with RET, TMEM127, 
MAX, NF1 and VHL gene products as well as with the succinate dehydrogenase complex. The 
mTOR protein is a kinase acting downstream in the phosphoinositide-3-kinase (PI3K)/AKT 
signalling pathway and forms two multiprotein complexes, named mTORC1 (sensitive to 
rapamycin) and mTORC2 (resistant to rapamycin). The mTORC1 complex is activated by 
diverse stimuli, such as growth factors, nutrients, oxygen availability, energy and stress 
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signals in order to control cell growth, proliferation and survival, whereas mTORC2 regulates 
the cytoskeleton function and is generally insensitive to nutrients and energy signals [7]. 
Hence, the mTOR pathway has been reported to be de-regulated in several human tumors, 
including - among others - neuroendocrine ones [11]. In PCCs, altered expression of mTOR-
pathway molecules (phosphorylated forms of AKT and the mTOR downstream effector S6) 
has been documented in small series [12,13]. Moreover, total mTOR protein was investigated 
in a larger series of PCC and PGL apparently with a very low proportion of tumours (5 out of 
100 cases) showing mTOR expression [14]. However, despite incomplete evidence of mTOR 
activation in PCC/PGL tumor tissues, therapeutic strategies selectively inhibiting mTOR have 
been tested both in vitro and in vivo. In fact, everolimus, a clinically used mTOR inhibitor, 
proved to be effective, although partially, in patients with progressive malignant PCCs/PGLs 
[15], whereas the dual inhibition of both mTORC1 and mTORC2 complexes has shown to be 
highly effective in PCC primary cell cultures and the MTT cell line [16].  
The present study was therefore designed to explore the activation pattern of mTOR 
signalling pathway in a large series of sporadic and hereditary PCC/PGL, in order to check its 
relation to clinical, pathological and genetic features.  
 
Materials and Methods 
 
Case series. A total of 222 genetically well-characterized PCCs and PGLs were included in 
the study from the databases of the following centres: Department of Pathology, Erasmus MC, 
Rotterdam, The Netherlands (7 cases); the Spanish National Cancer Research Centre (CNIO) 
and ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain (41 
cases); INSERM, UMR970, Paris-Cardiovascular Research Center (PARCC) ) and Biological 
Resources Center and Tumor Bank Platform, Hôpital européen Georges Pompidou (BB-0033-
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00063, 75015 Paris, France (78 cases); the Department of Experimental and Clinical 
Biomedical Sciences, University of Florence, Florence, Italy (51 cases) and the Division of 
Pathology, Department of Oncology, University of Turin at San Luigi Hospital, Orbassano, 
Turin, Italy (45 cases). Institutional review board approval was obtained for the study by each 
of the centers, and informed consent was obtained from all patients. The overall series 
included 178 PCC and 44 PGL. Fourteen cases were metastatic. The genetic characterization 
in all cases for the presence of germline mutations in the VHL, RET, MAX, TMEM127, SDHA, 
SDHB, SDHC, SDHD and FH and of somatic mutations in VHL, RET and MAX was 
performed in the enrolling centres as clinical routine work. The presence of NF1 mutations 
was determined in cases with clinically suspected neurofibromatosis type 1 (i.e. presence of 
neurofibromata and skin spots). Methodological conditions are available from the authors 
upon request. Moreover, H-RAS mutations were investigated in this series in a recent study by 
some of the present authors [5]. The baseline characteristics of the included samples are 
summarized in Table 1. 
 
Immunohistochemistry. Five tissue micro arrays were prepared at the Erasmus University 
Medical Centre and at the University of Turin for immunohistochemical analysis using the 
ATA-27 Automated Tissue Microarrayer (Beecher Instruments, Sun Prairie, WI, USA) or the 
semi-automated Quick-RAYTM tissue arrayer (Bio-Optica, Milan, Italy). For each case, two 
samples of tumor tissue were selected from a representative hematoxylin and eosin-stained 
slide, and tissue cylinders with a diameter of 1 mm were punched from the representative 
areas of the ‘donor’ block and brought into the ‘recipient’ paraffin block.  
All cases included on the five TMAs were analysed by means of immunohistochemistry using 
the following antibodies: mTOR (rabbit monoclonal, 7C10, diluted 1:50, Cell Signaling), 
phospho-mTOR (rabbit monoclonal, 49F9, Ser2448, diluted 1:100; Cell Signaling Tech, 
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Beverly, MA), phospho-p70S6K (mouse monoclonal, 1A5, Thr389, diluted 1:400; Cell 
Signaling), phospho-AMPK (rabbit monoclonal, 40H9, Thr172, diluted 1:100; Cell 
Signaling), phospho-AKT (rabbit monoclonal, 736E11, Ser473, diluted 1:40; Cell Signaling), 
phospho-4E-BP1 (rabbit monoclonal, diluted 1:300; Cell Signaling), p-S6 (rabbit polyclonal, 
2211, Ser 235/236, diluted 1:400; Cell Signaling), Rictor (rabbit monoclonal, diluted 1:100, 
Cell Signaling) and phospho-Raptor (rabbit polyclonal, diluted 1:100; Cell Signaling). 
Immunoreactions were revealed by means of a biotin-free, dextran-chain detection system 
(Envision, Dako, Glostrup, Denmark) and developed using diaminobenzidine (DAB) as the 
chromogen. For all antibodies, immunohistochemical staining was scored in each core by 
multiplying the most prevalent staining intensity (0=negative, 1=weak, 2=moderate, 
3=strong) and the quantity of staining (0-100%) giving a final IHC score (IHS) from 0 to 300. 
The mean score of the two cores for each tumor was recorded for subsequent statistical 
correlations.  All TMAs were evaluated by one of us (LO); moreover, random slides or cases 
with equivocal staining were assessed at a multihead microscope by two observers (LO and 
MV) to uniform the staining interpretation or reach a consensus. These data were used for 
statistical purposes. Moreover, a second blind round of evaluation of all TMA was performed 
by an independent investigator (EK) to test inter-observer agreement.  
 
Statistical analysis. The association between immunohistochemical findings, known clinical 
and pathological parameters and genotype was assessed by non-paired Student’s t test. The 
Spearman test was used to analyse the correlation index among the expression of markers and 
between two independent observers. The level of significance was set at p<0.05. Statistical 
analysis was performed using the GraphPad Prism 4 (GraphPad Software, Inc., San Diego, 
CA). 
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Results 
 
The mTOR pathway is activated in PCCs/PGLs. The functional activation of the mTOR 
pathway in the series analyzed was demonstrated by the positive correlation among most of 
the molecules investigated (Table 2). Total mTOR protein expression was positively 
associated to p-S6K, p-S6, p-AKT, p-Raptor and p-AMPK expression (Spearman’s 
correlation coefficient R: >0.3). The specific functional activation of the mTORC1 complex 
was strengthened by the reciprocal correlation of p-Raptor (which couples with mTOR in the 
mTORC1 complex) and both p-S6K and p-S6, and by the positive correlation of p-AMPK 
(which specifically interacts with the mTORC1 complex) with p-S6K, p-S6, p-AKT and p-
Raptor. By contrast, RICTOR (which couples with mTOR in the mTORC2 complex) was 
correlated with p-AKT, only. Phospho-mTOR protein, which represents the activated form of 
mTOR and interacts with both mTORC1 and mTORC2 complexes, was not significantly 
associated to a specific molecule, except for p-AKT. Robustness of immunohistochemical 
data was proved by the strong correlation between two observers evaluating independently all 
TMA (Table 3) 
 
The mTORC1 complex is over-expressed in PGLs. Molecules active in the mTOR pathway 
were differentially expressed in PCCs as compared to PGLs. Total mTOR, p-S6K and p-S6 
were all significantly over-expressed in PGLs than in PCCs. The mTORC1-associated 
molecules (p-Raptor and p-AMPK) showed the same profile. By contrast, p-mTOR and the 
mTORC2-associated molecule Rictor were over-expressed in PCCs (Table 4). When 
comparing tumor location, head and neck PGLs displayed a significantly higher expression of 
mTOR, p-S6K, p-S6, p-AMPK and p-Raptor as compared with abdominal PCC/PGLs 
(p<0.0001 for all markers). This association retained statistical significance restricting the 
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analysis to extra-adrenal and head and neck PGLs, only. Phospho-4EBP1 expression did not 
show significant differences between tumor type (PCC/PGL) and tumor location 
(abdominal/head and neck). None of the markers was significantly associated to the presence 
of malignant behaviour, except for p-mTOR which showed a higher mean IHS in benign 
cases. When comparing mean age at diagnosis, the expression of p-mTOR and Rictor was 
higher in older patients (using the median age of 45 years as the cut off), while the expression 
of p-AMPK and p-4EBP1 was higher in younger patients. Finally, any of the investigated 
markers was significantly associated to patients’ gender.  
 
mTOR pathway activation is associated with specific genotypes. The expression of the 
mTOR markers tested across the diverse PCC/PGL susceptibility genes and in cases with no 
germline or somatic mutations detected (n=109) was heterogeneous (Table 5). Highest levels 
of expression of mTOR, pS6K, pS6, p-Raptor and p-AMPK were detected in SDHX-mutated 
tumors. By contrast, TMEM127-mutated cases had very low protein expression levels of all 
markers. Cases with no known mutations showed expression levels for each marker generally 
close to the mean levels of the overall series. P-4EBP1 and p-AKT were the only markers that 
lacked any significant association with tumor genotype. For statistical comparison, all tumors 
from patients with known mutations in one of the PCC/PGL susceptibility genes were 
arbitrarily grouped into clusters, as proposed in the literature [17]: Cluster 1 included SDHX-, 
FH- and VHL-mutated tumors (n=53), whereas Cluster 2 included NF1, RET, TMEM127, 
MAX and H-RAS PCC/PGL (n=57). Cluster 1 tumors had significantly higher total mTOR, p-
Raptor and p-S6 expression than Cluster 2 PCC/PGL. In contrast, p-mTOR and Rictor 
expression were significantly higher in Cluster 2 tumors as compared to Cluster 1 tumors. 
Among genes in Cluster 2, a significant difference was observed between MAX and H-RAS 
for p-mTOR expression (p=0.0170), and between RET and H-RAS for p-S6K expression 
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(p=0.0128). More interestingly, within Cluster 1, VHL- and SDHX-mutated cases showed 
significantly different mTOR pathway profiles. Molecules active in the mTORC1 complex (p-
AMPK and p-Raptor) and mTOR itself were significant over-expressed whereas p-mTOR 
expression was reduced in SDHX- as compared to VHL-mutated tumors (Figure 1). Finally, 
restricting the analysis to PGL cases only, mTORC1 complex was over-expressed in SDHX 
mutated (28 cases) vs not mutated (14 cases) tumors, whereas p-mTOR expression was 
reduced (Figure 2). 
 
Discussion 
 
The mTOR signalling pathway in PCC/PGLs has attracted research interest because cluster 2 
PCC/PGLs are associated with a de-regulation of this pathway and components of the mTOR 
pathway have signalling interactions with SDHX and VHL gene products (i.e. cluster 1 
PCC/PGLs) as well. Therefore, the use of drugs targeting the mTOR pathway has been 
considered suitable in PCC/PGL patients.  
In this study, we investigated the immunohistochemical expression of mTOR-signalling 
components in a very large series of PCC/PGLs. We correlated the expression of a variety of 
markers acting in the mTOR pathway with major clinical data and genotype of the tumors. 
Although a few studies have investigated the protein expression of single or various 
components of the mTOR pathway [12-14] in this setting, a comprehensive assessment of all 
key members of this intracellular signalling cascade in a genetically well-characterized set of 
PCC/PGLs has not been performed. Examining the entire population, a substantial activation 
of the mTOR pathway emerged by the positive correlation between mTOR protein expression 
and its down and upstream regulators, with special reference to those acting in the mTORC1 
complex. Our data are partly in contrast with the findings by Pinato [14], who found a very 
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low expression of mTOR and AKT in a series of PCC and PGL. However, in the present 
study the protein expression data were supported by the integrated analysis of several 
molecules active in the same pathway which were all consistent and significantly correlated 
with each other. Phosphorylated-mTOR was not directly correlated with mTOR and other 
proteins active in the mTORC1 complex except for p-AKT. These findings are probably 
related to the fact that the phosphorylated form of mTOR is also active in the mTORC2 
complex, thus its detection at the tissue level is the consequence of more complex stimuli.  
When trying to compare the patterns of expression of all molecules investigated with major 
clinical and pathological parameters, it was clearly evident that PCC and PGL have opposite 
profiles of activation. In fact, mTORC1-active molecules and mTOR itself were over-
expressed in PGLs as compared to PCCs. This same profile was observed in head and neck 
PGLs when compared to extra-abdominal tumors. By contrast, mTORC2 protein Rictor and 
p-mTOR were over-expressed in PCCs as compared to PGLs, but failed to be significantly 
different when comparing head and neck versus extra-abdominal PGLs. With regard to other 
clinical or pathological parameters, all markers failed to show relevant associations. Phospho-
mTOR was significantly over-expressed in non-metastatic cases, a finding which is in 
agreement with what observed by Ghayee and coworkers [13] in a smaller series, but this 
association is more probably the result of the higher expression in PCC cases observed in our 
entire population. Hence, we might argue that the mTOR pathway is expressed in both benign 
and malignant PCC/PGLs and mTOR inhibition might be a successful therapy target in 
malignant PCC/PGL cases which need medical treatment for disease control.  
A further aim of this study was to extensively explore the association between mTOR 
activation status and genotype of PCC/PGL cases. The hypothesis of specific genetic-driven 
activation profiles of the mTOR pathway in PCC/PGLs partly stemmed from previous 
observations by some of the present authors on the association between mTOR activation and 
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Ret mutational status in medullary thyroid carcinoma [10]. This hypothesis was also partly 
sustained by Pinato and co-workers who found, although at very low levels - as commented 
above - a preferential expression of mTOR and AKT in SDHX-mutated tumors [14]. 
Comparing genes grouped into the two major molecular clusters, namely SDHX and VHL in 
cluster 1 and NF1, RET, TMEM127, MAX and H-RAS in cluster 2 PCC/PGL, it was strongly 
evident that mTORC1 complex molecules (including p-S6, p-Raptor and mTOR itself) were 
over-expressed in Cluster 1 tumors, whereas phospho-mTOR and Rictor were over-expressed 
in Cluster 2 tumors. It is worth to notice that restricting the analysis to Cluster 1 a significant 
over-expression of some of the above mentioned molecules (p-Raptor and mTOR itself) 
together with p-AMPK (all belonging to the mTORC1 complex) was observed in SDHX as 
compared to VHL- mutated tumors. Moreover, mTORC1 complex over-activation in SDHX 
mutated tumors was significant also in the PGL group examined separately. Interestingly, our 
data are in agreement with a previous study describing the increased expression of phospho-
p70S6K in a subgroup of Cluster 1 cases enriched for SDHx mutations as compared to Cluster 1 
cases enriched for VHL mutations [18]. 
These findings overall suggest two major issues: first, that although grouped into major 
molecular clusters, PCC and PGL with different genetic profiles are characterized by specific 
and more heterogeneous intracellular signalling activation patterns; second, that if the genetic 
landscape of tumors is a major responsible for mTOR activation in PCC/PGL, the 
hypothetical strategy of mTOR-targeting therapies in PCC/PGL should take into 
consideration not only the biological behaviour of tumors but also their genetic characteristic 
to be of clinical meaningfulness. However, our data are descriptive in nature and validation of 
immunohistochemical biomarkers on tissue microarrays is methodologically limited in part, 
therefore their potential utility need to be validated in the clinical practice and corroborated by 
functional pharmacogenomic studies. 
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In summary, our data show that the mTOR pathway is activated in a relevant proportion of 
PCC/PGLs, with a preferential over-expression of mTORC1 complex proteins in PGLs of the 
head and neck and/or harbouring SDHX mutations.  
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Figure Legends 
 
Figure 1. Representative immunohistochemical pictures (above) and boxplots (below) 
showing the differential expression of mTOR-pathway molecules in VHL as compared to 
SDHX mutated tumors.  
 
Figure 2. Boxplots showing the differential expression of mTOR-pathway molecules 
reaching statistical significance in non-mutated as compared to SDHX-mutated PGLs. 
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Table 1. Baseline characteristics of patients. 
Baseline characteristic n = 222 
Gender   
Male 98 
Female 124 
Age   
< mean 45 103 
> mean 45 119 
PCC genotype 177 
VHL germline/somatic 14/3 
RET germline/somatic 30/3 
NF1 germline/somatic 6/4 
MAX germline/somatic 5/1 
TMEM127 germline 2 
SDHB germline 2  
SDHD germline 3 
H-RAS somatic 6 
No mutation found 98 
EA PGL genotype 21 
VHL germline/somatic 
NF1 germline 
1/1 
1 
SDHB germline 6 
SDHC germline 2 
SDHD germline 2 
No mutation found 8 
HNPGL genotype 22 
SDHB germline 5 
SDHD germline 13 
SDHX * germline 
No mutation found 
1 
3 
META genotype 2 
SDHB germline 1 
FH germline 1 
Behaviour   
Non-metastatic 208 
Metastatic 14 
 
PCC = pheochromocytoma; EA PGL = extra-adrenal paraganglioma; HNPGL = head&neck 
paraganglioma; meta = metastasis; *SDHB immunonegative, but no 
SDHB/SDHC/SDHD/SDHAF2 mutation identified with Sanger sequencing.  
  
20 
 
Table 2. Reciprocal correlations among markers investigated. 1 
 p-mTOR p-S6K p-S6 p-AKT p-RAPTOR RICTOR p-AMPK p-4EBP-1 
mTOR R: 0.1019 
p: 0.1347 
R: 0.39 
p: <0.0001 
R: 0.45 
p: <0.0001 
R: 0.34 
p: <0.0001 
R: 0.37 
p: <0.0001 
R: 0.11 
p: 0.09 
R: 0.51 
p: <0.0001 
R: 0.23 
p: 0.001 
p-mTOR - R: -0.02 
p: 0.82 
R: 0.02 
P: 0.72 
R: 0.34 
p: <0.0001 
R: 0.04 
p: 0.59 
R: 0.21 
p: 0.002 
R: 0.15 
p: 0.02 
R: 0.07 
p: 0.32 
p-S6K - - R: 0.42 
p: <0.0001 
R: 0.18 
p: 0.01 
R: 0.40 
p: <0.0001 
R: -0.01 
p: 0.89 
R: 0.50 
p: <0.0001 
R: 0.29 
p: <0.0001 
p-S6 - - - R: 0.19 
p: 0.006 
R: 0.47 
p: <0.0001 
R: 0.03 
P: 0.66 
R: 0.41 
p: <0.0001 
R: 0.22 
p: 0.001 
p-AKT - - - - R: 0.16 
p: 0.02 
R: 0.38 
p: <0.0001 
R: 0.38 
p: <0.0001 
R: 0.18 
p: 0.008 
p-RAPTOR - - - - - R: 0.00 
p: 0.94 
R: 0.32 
p: <0.0001 
R: 0.13 
p: 0.06 
RICTOR - - - - - - R: 0.16 
p: 0.02 
R: 0.16 
p: 0.02 
p-AMPK - - -  - - - R: 0.28 
p: <0.0001 
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Table 3. Interobserver agreement.  3 
 4 
IHC marker Observer LO vs Observer 
EK - Spearman’s correlation 
mTOR R: 0.85 
p: <0.0001 
p-mTOR R: 0.92 
p: <0.0001 
p-S6K R: 0.84 
p: <0.0001 
p-S6 R: 0.72 
p: <0.0001 
p-AKT R: 0.86 
p: <0.0001 
p-RAPTOR R: 0.88 
p: <0.0001 
RICTOR R: 0.87 
p: <0.0001 
p-AMPK R: 0.95 
p: <0.0001 
p-4EBP-1 R: 0.91 
p: <0.0001 
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Table 4. Correlation of mTOR pathway molecules with clinical and pathological characteristics  6 
 mTOR p-mTOR p-S6K p-S6 p-AKT p-Raptor Rictor p-AMPK p-4EBP1 
 mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean 
± SE p 
mean 
± SE p 
mean ± 
SE p 
PCC 
42.0 ± 
4.7  
91.1 ± 
5.9  
30.7 ± 
3.8  
14.0 ± 
2.6  
144.7 ± 
6.1  
82.8 ± 
6.1  
155.0 
± 6.3  
45.9 ± 
6.0  
38.8 ± 
5.1   
PGL 
101.9 ± 
16.5 <0.001 
42.0 ± 
9.1 <0.001 
53.3 ± 
6.9 0.001 
42.3 ± 
8.8 <0.001 
130 ± 
10.9 0.25 
144.2 ± 
16.2 <0.001 
110.1 
± 12.3 <0.001 
89.5 ± 
15.6 0.004 
57.3 ± 
12.9 0.17 
EAPGL 
36.9 ± 
12.0  
44.3 + 
13.7  
31.7 + 
9.7  
13.5  ± 
5.3  
114.0 + 
15.8  
81.0  ± 
17.9  
122.1 
± 20.2  
52.4 ± 
18.4  
74.3 ± 
20.1   
HNPGL 
163.9 ± 
23.5 <0.001 
39.8 ± 
12.3 0.72 
75.0 ± 
7.3 0.001 
69.7 ± 
14.2 <0.001 
145.2 ± 
14.6  0.19 
204.5 ± 
19.4 <0.001 
   98.1 
± 14.0 0.55 
125.0 
± 22.7 0.015 
41.1 ± 
16.0 0.16 
non-mets 
54.7 ± 
5.5  
84.2 ± 
5.4  
34.8 ± 
3.3  
18.8 ± 
2.8  
143.7 ± 
5.5  
93.0 ± 
6.1  
148.0 
± 5.9  
55.0 ± 
6.0  
40.4 ± 
4.8   
mets 
35.8 ± 
11.6 0.86 
35 ± 
11.4 0.02 
37.3 ± 
11.9 0.60 
28.6 ± 
18.6 0.82 
114.6 ± 
16.8 0.16 
130.4 ± 
29.4 0.24 
144.6 
± 28.0 0.75 
42.3 ± 
19.5 0.66 
78.6 ± 
27.9 0.33 
Female 
51.7 ± 
7.0  
88.1 ± 
7.3  
34.2 ± 
4.3  
13.7 ± 
2.8  
136.9 ± 
7.1  
88.2 ± 
7.8  
150.2 
± 7.9  
54.1  
± 8.0  
39.3 ± 
6.2   
Male 
56.0 ± 
7.9 0.65 
72.7 ± 
7.4 0.16 
35.9 ± 
4.6 0.87 
26.7 ± 
5.2 0.13 
148.0 ± 
7.9 0.38 
104.4 ± 
9.3 0.19 
144.6 
± 8.4 0.64 
54.3 ± 
8.4 0.80 
47.3 ± 
7.7 0.31 
age<mean 
54.9 ± 
7.8  
67.4 ± 
7.2  
39.7 ± 
5.0  
26.0 ± 
4.9  
134.0 ± 
7.8  
105.8 ± 
9.5  
134.4 
± 8.6  
68.6 ± 
9.5  
51.9 ± 
7.8   
age>mean 
52.5 ± 
7.0 0.98 
93.1 ± 
7.3 0.01 
30.8 ± 
3.9 0.24 
13.7 ± 
3.0 0.35 
148.8 ± 
7.2 0.11 
86.2 ± 
7.5 0.19 
159.5 
± 7.5 0.02 
41.7 ± 
6.8 0.04 
34.9 ± 
5.9 0.04 
 7 
Note: PCC= pheochromocytoma; PGL= paraganglioma; EAPGL= extra adrenal paraganglioma; HNPGL= head and neck paraganglioma; mets: 8 
metastatic.  9 
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Table 5. Correlation of mTOR pathway components with genotype  11 
 mTOR p-mTOR p-S6K p-S6 p-AKT p-Raptor Rictor p-AMPK p-4EBP1 
 mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
mean ± 
SE p 
H-RAS (#6) 
58.33 ± 
23.86  
166.67 
± 28.07   5 ± 3.16  
10 ± 
6.32   
183.3 ± 
30.73  
73.3 ± 
29.20  
153.33 ± 
18.65  
33.33 ± 
24.72  
40.83 ± 
20.02    
MAX (#6) 30 ± 30  
37 ± 
13.38   18 ± 7.84  0   
130.0 ± 
48.99  
43 ± 
28.27  
100 ± 
25.0  
10.0 ± 
10  
108.33 
± 49.20  
NF1 (#10) 
45.91 ± 
20.64  
73.18 ± 
16.79   
21,36 ± 
5.80  
20 ± 
11.06   
159.1 ± 
25.95  
102.3 ± 
23.94  
137.27 ± 
28.99  
31.82 ± 
13.94  
45.45 ± 
31.23  
RET (#33) 
41.29 ± 
12.64  
110.61 
± 13.90   
61,56 ± 
11.28  
16,6 ± 
7.23   
142.6 ± 
15.62  
90 ± 
16.58  
167.58 ± 
14.55  
103.03 
± 19.09  
48.28 ± 
12.76  
TMEM127 
(#2) 50 ± 50.0  
12.5 ± 
12.5   10 ± 0  0   
25.0 ± 
25.0  7.5 ± 7.5  50 ± 50  
25.0 ± 
25  0.0  
SDHX (#35) 
118,09 ± 
18.60   
24.24 ± 
6.36   
62,58 ± 
7.74   
49.47 ± 
10.80   
128.9 ± 
10.64   
180.0 ± 
16.71  
110.29 ± 
13.23   
108.82 
± 18.58   
54.57 ± 
12.58  
FH (#1) 0  0  0  0   100  100   300  0.0  0.0   
VHL (#17) 
26.32 ± 
10.38   
90 ± 
20.88   
29,11 ± 
8.90   
28.16 ± 
11.24   
114.2 ± 
16.30   
87.1 ± 
16.32  
128.16 ± 
17.98   
5.26 ± 
3.62   
60.26 ± 
22.51  
NO 
MUT*(#109) 
36.09 ± 
7.05 0.002 
85.43 ± 
10.55 <0.001 
18.48 ± 
4.05 <0.001 
13,80 ± 
5.92 0.003 
149.81 ± 
7.51 0.12 
75.65 ± 
7.14 < 0.001 
137.5 ± 
10.04 0.031 
26.09 ± 
8.48 <0.001 
26.91 ± 
8.32 0.33 
CLUSTER1 
(#53) 
86.83 ± 
14.01  
45.29 ± 
9.3  
51.24 ± 
6.32  
42.16 ± 
8.16   
124.15 ± 
9.09  
149.15 ± 
13.74  
116.06 ± 
10.81  
73.08 ± 
13.97  
40.83 ± 
20.02 ±   
CLUSTER2 
(#57) 
43.36 ± 
8.95 0.012 
99.39 ± 
10.26 <0.001 
41.88 ± 
7.24 0.21 
14.45 ± 
4.69 <0.001 
144.82 ± 
11.88 0.18 
83.60 ± 
11.48 <0.001
150.18 ± 
11.03 0.018 
71.05 ± 
12.64 0.9 
108.33 
± 49.20 0.65 
 12 
Note: *: p value as compared to cases with any type of mutation. 13 
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